Approval Status
Approval April 1998

Treatment for
slow white blood cell recovery following chemotherapy

Hematology , Cancer & Oncology

Neupogen has been approved for its fifth indication: to reduce the time to neutrophil recovery and the duration of fever following chemotherapy treatment in patients being treated for acute myeologenous leukemia. Patients with this type of leukemia can now receive Neupogen to improve their ability to tolerate essential chemotherapy treatments.

Neupogen Drug Information

The Neupogen drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top